CLAIMS

1. An RNAi agent comprising a sense strand comprising a nucleobase sequence according to any one of SEQ ID NO: 302, 282-284, 286-290, 295-297, 300, 306-315, and 319-321, and an antisense strand at least partially complementary to the sense strand.

2. The RNAi agent of claim 1, wherein the antisense strand comprises a nucleobase sequence according to any one of SEQ ID NO: 152, 155-160, 165-171, 174-177, and 179-181.

3. The RNAi agent of claim 1 or 2, wherein the sense strand comprises a nucleotide sequence according to any one of SEQ ID NO: 204-206, 208-212, 219-223, 226, 229, 234-247, 252-255, and 273.

4. The RNAi agent of any one of claims 1-3, wherein the sense strand has a structure of any one of SEQ ID NO: 204-206, 208-212, 219-223, 226, 229, 234-247, 252-255, and 273.

5. The RNAi agent of any one of claims 1-4, wherein the antisense strand comprises a nucleotide sequence according to any one of SEQ ID NO: 72-76, 78, 79, 88-92, 98-100, 108-124, and 126-130.

6. The RNAi agent of any one of claims 1-5, wherein the antisense strand has a structure of any one of SEQ ID NO: 72-76, 78, 79, 88-92, 98-100, and 108-124, 126-130.

7. The RNAi agent of any one of claims 1-6, wherein the RNAi agent comprises an antisense strand and a sense strand having modified nucleotide sequences, the RNAi agent having the duplex structure of AD04001 (SEQ ID NO: 72 and SEQ ID NO: 204); AD04002 (SEQ ID NO: 73 and SEQ ID NO: 204); AD04003 (SEQ ID NO: 74 and SEQ ID NO: 205); AD04004 (SEQ ID NO: 72 and SEQ ID NO: 206); AD04005 (SEQ ID NO: 75 and SEQ ID NO: 212); AD04008 (SEQ ID NO: 78 and SEQ ID NO: 208); AD04009 (SEQ ID NO: 76 and SEQ ID NO: 209); AD04010 (SEQ ID NO: 79 and SEQ ID NO: 211); AD04422 (SEQ

ID NO: 74 and SEQ ID NO: 219); AD04423 (SEQ ID NO: 88 and SEQ ID NO: 205); AD04425 (SEQ ID NO: 89 and SEQ ID NO: 20); AD04426 (SEQ ID NO: 90 and SEQ ID NO: 221); AD04427 (SEQ ID NO: 90 and SEQ ID NO: 222); AD04428 (SEQ ID NO: 91 and SEQ ID NO: 221); AD04429 (SEQ ID NO: 91 and SEQ ID NO: 222); AD04430 (SEQ ID NO: 92 and SEQ ID NO: 223); AD04438 (SEQ ID NO: 98 and SEQ ID NO: 226); AD04439 (SEQ ID NO: 99 and SEQ ID NO: 226); AD04511 (SEQ ID NO: 100 and SEQ ID NO: 229); AD04581 (SEQ ID NO: 108 and SEQ ID NO: 211); AD04583 (SEQ ID NO: 109 and SEQ ID NO: 234); AD04584 (SEQ ID NO: 110 and SEQ ID NO: 234); AD04585 (SEQ ID NO: 111 and SEQ ID NO: 235); AD04586 (SEQ ID NO: 112 and SEQ ID NO: 234); AD04587 (SEQ ID NO: 109 and SEQ ID NO: 236); AD04588 (SEQ ID NO: 110 and SEQ ID NO: 237); AD04590 (SEQ ID NO: 113 and SEQ ID NO: 211); AD04591 (SEQ ID NO: 108 and SEQ ID NO: 238); AD04592(SEQ ID NO: 74 and SEQ ID NO: 239); AD04593 (SEQ ID NO: 114 and SEQ ID NO: 240); AD04594 (SEQ ID NO: 115 and SEQ ID NO: 240); AD04595 (SEQ ID NO: 116 and SEQ ID NO: 241); AD04596 (SEQ ID NO: 117 and SEQ ID NO: 241; AD04597 (SEQ ID NO: 114 and SEQ ID NO: 242); AD04598 (SEQ ID NO: 115 and SEQ ID NO: 243); AD04599 (SEQ ID NO: 118 and SEQ ID NO: 220); AD04734 (SEQ ID NO: 119 and SEQ ID NO: 235); AD04771 (SEQ ID NO: 120 and SEQ ID NO: 244); AD04772 (SEQ ID NO: 121 and SEQ ID NO: 245); AD04773 (SEQ ID NO: 122 and SEQ ID NO: 244); AD04774 (SEQ ID NO: 123 and SEQ ID NO: 246); AD04775 (SEQ ID NO: 123 and SEQ ID NO: 247); AD04822 (SEQ ID NO: 124 and SEQ ID NO: 244); AD04872 (SEQ ID NO: 126 and SEQ ID NO: 252); AD04873 (SEQ ID NO: 127 and SEQ ID NO: 252); AD04874 (SEQ ID NO: 128 and SEQ ID NO: 253); AD04875 (SEQ ID NO: 129 and SEQ ID NO: 254); AD04876 (SEQ ID NO: 130 and SEQ ID NO: 255); AD04962 (SEQ ID NO: 111 and SEQ ID NO: 244) or AD05164 (SEQ ID NO: 126 and SEQ ID NO: 273).

8. An RNAi agent comprising an antisense strand comprising a nucleobase sequence according to any one of SEQ ID NO: 171, 152, 155-160, 165-170, and 174-181, and a sense strand at least partially complementary to the antisense sense strand.

9. The RNAi agent of claim 8, wherein the sense strand comprises a nucleobase sequence according to any one of SEQ ID NO: 282-287, 289, 290, 294-302, 306-315, and 318-321.

10. The RNAi agent of claim 8 or 9, wherein the antisense strand comprises a nucleotide sequence according to any one of SEQ ID NO: 65, 72-79, 88-100, and 108-130.

11. The RNAi agent of any one of claims 8-10, wherein the antisense strand has a structure of any one of SEQ ID NO: 65, 72-79, 88-100, and 108-130.

12. The RNAi agent of any one of claims 8-11, wherein the sense strand comprises a nucleotide sequence according to any one of SEQ ID NO: 204-209, 211, 212, 219-229, 234-248, 251-255, and 273.

13. The RNAi agent of any one of claims 7-12, wherein the sense strand has a structure of any one of SEQ ID NO: 204-209, 211, 212, 219-229, 234-248, 251-255, and 273.

14. The RNAi agent of any one of claims 7-13, wherein the RNAi agent comprises an antisense strand and a sense strand having modified nucleotide sequences, the RNAi agent having the duplex structure of AD04001 (SEQ ID NO: 72 and SEQ ID NO: 204); AD04002 (SEQ ID NO: 73 and SEQ ID NO: 204); AD04003 (SEQ ID NO: 74 and SEQ ID NO: 205); AD04004 (SEQ ID NO: 72 and SEQ ID NO: 206); AD04005 (SEQ ID NO: 75 and SEQ ID NO: 212); AD04006 (SEQ ID NO: 76 and SEQ ID NO: 207); AD04007 (SEQ ID NO: 77 and SEQ ID NO: 207); AD04008 (SEQ ID NO: 78 and SEQ ID NO: 208); AD04009 (SEQ ID NO: 76 and SEQ ID NO: 209); AD04010 (SEQ ID NO: 79 and SEQ ID NO: 211); AD04422 (SEQ ID NO: 74 and SEQ ID NO: 219); AD04423 (SEQ ID NO: 88 and SEQ ID NO: 205); AD04425 (SEQ ID NO: 89 and SEQ ID NO: 20); AD04426 (SEQ ID NO: 90 and SEQ ID NO: 221); AD04427 (SEQ ID NO: 90 and SEQ ID NO: 222); AD04428 (SEQ ID NO: 91 and SEQ ID NO: 221); AD04429 (SEQ ID NO: 91 and SEQ ID NO: 222); AD04430 (SEQ ID NO: 92 and SEQ ID NO: 223); AD04431 (SEQ ID NO: 74 and SEQ ID NO: 224); AD04432 (SEQ ID NO: 74 and SEQ ID NO: 225); AD04433 (SEQ ID NO: 93 and SEQ ID NO: 207); AD04434 (SEQ ID NO: 94 and SEQ ID NO: 207); AD04435 (SEQ ID NO: 95 and SEQ ID NO: 207); AD04436 (SEQ ID NO: 97 and SEQ ID NO: 207); AD04437 (SEQ ID NO: 96 and SEQ ID NO: 207); AD04438 (SEQ ID NO: 98 and SEQ ID NO: 226); AD04439 (SEQ ID NO: 99 and SEQ ID NO: 226); AD04440 (SEQ ID NO: 78 and SEQ ID NO: 227); AD04511 (SEQ ID NO: 100 and SEQ ID NO: 229); AD04581 (SEQ ID NO: 108

and SEQ ID NO: 211); AD04583 (SEQ ID NO: 109 and SEQ ID NO: 234); AD04584 (SEQ ID NO: 110 and SEQ ID NO: 234); AD04585 (SEQ ID NO: 111 and SEQ ID NO: 235); AD04586 (SEQ ID NO: 112 and SEQ ID NO: 234); AD04587 (SEQ ID NO: 109 and SEQ ID NO: 236); AD04588 (SEQ ID NO: 110 and SEQ ID NO: 237); AD04590 (SEQ ID NO: 113 and SEQ ID NO: 211); AD04591 (SEQ ID NO: 108 and SEQ ID NO: 238); AD04592(SEQ ID NO: 74 and SEQ ID NO: 239); AD04593 (SEQ ID NO: 114 and SEQ ID NO: 240); AD04594 (SEQ ID NO: 115 and SEQ ID NO: 240); AD04595 (SEQ ID NO: 116 and SEQ ID NO: 241); AD04596 (SEQ ID NO: 117 and SEQ ID NO: 241; AD04597 (SEQ ID NO: 114 and SEQ ID NO: 242); AD04598 (SEQ ID NO: 115 and SEQ ID NO: 243); AD04599 (SEQ ID NO: 118 and SEQ ID NO: 220); AD04734 (SEQ ID NO: 119 and SEQ ID NO: 235); AD04771 (SEQ ID NO: 120 and SEQ ID NO: 244); AD04772 (SEQ ID NO: 121 and SEQ ID NO: 245); AD04773 (SEQ ID NO: 122 and SEQ ID NO: 244); AD04774 (SEQ ID NO: 123 and SEQ ID NO: 246); AD04775 (SEQ ID NO: 123 and SEQ ID NO: 247); AD04822 (SEQ ID NO: 124 and SEQ ID NO: 244);AD04871 (SEQ ID NO: 125 and SEQ ID NO: 251); AD04872 (SEQ ID NO: 126 and SEQ ID NO: 252); AD04873 (SEQ ID NO: 127 and SEQ ID NO: 252); AD04874 (SEQ ID NO: 128 and SEQ ID NO: 253); AD04875 (SEQ ID NO: 129 and SEQ ID NO: 254); AD04876 (SEQ ID NO: 130 and SEQ ID NO: 255); AD04962 (SEQ ID NO: 111 and SEQ ID NO: 244) or AD05164 (SEQ ID NO: 126 and SEQ ID NO: 273).

15. The RNAi agent of any one of claims 1-14, wherein the RNAi agent comprises a sense strand linked at the 5' terminal end to NAG37s and having the structure (NAG37)s-(invAb)sguggacuuCfUfCfucaauuuucus(invAb) (SEQ ID NO: 252) and an antisense strand having the structure asGfsasAfaAfuUfgAfgAfgAfaGfuCfcasc (SEQ ID NO: 126) .

16. The RNAi agent of any one of claims 1-15, wherein at least one nucleotide of the sense strand and/or at least one nucleotide of the antisense strand of the RNAi agent is a modified nucleotide and/or has a modified internucleoside linkage.

17. The RNAi agent of any one of claims 1-16, wherein all or substantially all of the nucleotides in the sense strand of the RNAi agent are modified nucleotides.

18. The RNAi agent of any one of claims 1-17, wherein all or substantially all of the nucleotides in the antisense strand of the RNAi agent are modified nucleotides.

19. The RNAi agent of any one of claims 1-18, wherein the sense strand and the antisense strand are each 17 to 30 nucleotides in length.

20. The RNAi agent of any of claims 1-19, wherein the RNAi agent is conjugated to a targeting ligand.

21. The RNAi agent of claim 20, wherein the targeting ligand comprises N-acetyl-galactosamine.

22. The RNAi agent of claim 21, wherein the targeting ligand is (NAG13), (NAG13)s, (NAG18), (NAG18)s, (NAG24), (NAG24)s, (NAG25), (NAG25)s, (NAG26), (NAG26)s, (NAG27), (NAG27)s, (NAG28), (NAG28)s, (NAG29), (NAG29)s, (NAG30), (NAG30)s, (NAG31), (NAG31)s, (NAG32), (NAG32)s, (NAG33), (NAG33)s, (NAG34), (NAG34)s, (NAG35), (NAG35)s, (NAG36), (NAG36)s, (NAG37), (NAG37)s, (NAG38), (NAG38)s, (NAG39), or (NAG39)s.

23. The RNAi agent of any one of claims 20-22, wherein the targeting ligand is conjugated to the sense strand of the RNAi agent.

24. The RNAi agent of any one of claims 20-23, wherein the targeting ligand is conjugated to the antisense strand of the RNAi agent.

25. The RNAi agent of any one of claims 1-24, wherein the RNAi agent is in a salt form.

26. The RNAi agent of any one of claims 1-25, wherein the RNAi agent is in a sodium salt form.

27. The RNAi agent of any one of claims 1-26, wherein the RNAi agent is in a sodium salt form dissolved in an aqueous solution.

28. A method of making the RNAi agent of any one of claims 1-27, comprising:
synthesizing the sense strand of the RNAi agent,
synthesizing the antisense strand of the RNAi agent, and
annealing the sense and antisense strands to make the RNAi agent.

29. A composition comprising the RNAi agent of any one of claims 1-27, further comprising a pharmaceutically acceptable excipient.

30. The RNAi agent of any one of claims 1-27 or the composition of claim 29, for use in a method for inhibiting expression of a Hepatitis B Virus gene in a subject.

31. The RNAi agent of any one of claims 1-27 or the composition of claim 29, for use in a treatment of an HBV infection and/or a disease, disorder, or condition associated with an HBV infection in a subject.

32. The RNAi agent of any one of claims 1-27 or the composition of claim 29, for use in a treatment of a chronic HBV infection.

33. The RNAi agent of any one of claims 1-27 or the composition of claim 29, for use in a treatment of a chronic Hepatitis D virus (HDV) infection.

34. The RNAi agent or composition of claim 31, wherein the disease, disorder, or condition associated with HBV infection is a chronic liver disease or disorder, liver inflammation, a fibrotic condition, a proliferative disorder, hepatocellular carcinoma, Hepatitis D virus infection, or acute HBV infection.

35. The RNAi agent or composition of claims 31 or 34, wherein the subject has at least one of Hepatitis D Virus (HDV) and Human Immunodeficiency Virus (HIV).

36. The RNAi agent or composition of claim 35, wherein the subject is infected with HBV and at least one of HDV or HIV.

37. The RNAi agent or composition of claim 31, wherein the disease, disorder, or condition associated with HBV infection is a chronic liver disease or disorder.

38. The RNAi agent or composition of claim 31, wherein the disease, disorder, or condition associated with HBV infection is liver inflammation.

39. The RNAi agent or composition of claim 31, wherein the disease, disorder, or condition associated with HBV infection is a fibrotic condition.

40. The RNAi agent or composition of claim 31, wherein the disease, disorder, or condition associated with HBV infection is a proliferative disorder.

41. The RNAi agent or composition of claim 31, wherein the disease, disorder, or condition associated with HBV infection is hepatocellular carcinoma.

42. The RNAi agent or composition of claim 31, wherein the disease, disorder, or condition associated with HBV infection is an (HDV) infection.

43. The RNAi agent or composition of claim 42, wherein the HDV infection is a chronic HDV infection.